Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Behind SAB’s rapid response to COVID-19

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

Sandi Wong, Assistant Editor
April 24, 2020 11:48 PM UTC

SAB had already been working with the U.S. Department of Defense to prepare its human polyclonal antibody platform for rapid responses to new infectious diseases when COVID-19 emerged. The company has since applied its DiversitAb platform to generate SAB-185, a cow-derived human polyclonal antibody therapy that is more consistent and easier to scale up than convalescent plasma from recovered COVID-19 patients.

SAB Biotherapeutics Inc. co-founder and CEO Eddie Sullivan told BioCentury it expects initial lots of SAB-185, which targets the SARS-CoV-2 spike protein, to be ready for clinical testing in early summer. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Sab Biotherapeutics Inc.